Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1062P - Real-world data on clinical outcome and tolerability in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in the Netherlands

Date

16 Sep 2021

Session

ePoster Display

Topics

Immunotherapy

Tumour Site

Non-Melanoma Skin Cancers

Presenters

Maartje Rohaan

Citation

Annals of Oncology (2021) 32 (suppl_5): S867-S905. 10.1016/annonc/annonc706

Authors

M.W. Rohaan1, M.L. Duizer2, L.A. Devriese3, S. Wilgenhof1, C.M. Van Herpen2, J.B.A.G. Haanen1

Author affiliations

  • 1 Medical Oncology Department, Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 2 Medical Oncology Department, Radboud University Medical Center, 6525 GA - Njimegen/NL
  • 3 Medical Oncology Department, UMC-University Medical Center Utrecht, 3584 CX - Utrecht/NL
More

Abstract 1062P

Background

Cutaneous squamous cell carcinoma (CSCC) is the second most common cutaneous malignancy and patients with locally advanced or metastatic disease have a poor prognosis. Cemiplimab, a monoclonal anti-PD-1 antibody, has recently been approved by the FDA and EMA for this patient cohort based on single-arm phase II studies. Real-world data on clinical outcome and tolerability is still scarce.

Methods

In this retrospective cohort analysis, patients treated with cemiplimab for advanced CSCC from 3 sites in the Netherlands from November 2018 until August 2020 were evaluated for response and toxicity. Collected data comprised patient’s demographics, tumor characteristics and treatment course. Clinical response, adverse events (AE), progression-free survival (PFS) and overall survival (OS) were assessed.

Results

In total, 66 patients (50 male, 16 female, median age 75; range 30-93 years) with unresectable locoregional (41 (62%) patients) or metastatic (25 (38%) patients) CSCC treated with flatdose cemiplimab 350mg Q3W were included. All but 8 patients (88%) had severe comorbidities, the most common site of the primary tumor was the head or neck (79%) and 7 (11%) patients were pretreated with systemic therapy. A median of 6.5 doses of cemiplimab (range 1-31 doses) were administered and treatment was well-tolerated, with grade 1-2 AEs in 70% and grade 3-4 AEs in 17% of patients. An objective clinical response was seen in 33 (50%) patients, of whom 9 (14%) reached CR and 24 (36%) PR. With a median follow-up of 11.7 months (95% CI 8.4-15.0 months), median PFS was 17.3 months and median OS was not reached. In 39 (59%) patients treatment was discontinued, mostly due to disease progression (49%). In 8 (21%) patients with ongoing response treatment was stopped after a median of 11.5 months (range 2.9-15.2 months).

Conclusions

In this real-world cohort of advanced CSCC patients, cemiplimab demonstrated to be well-tolerated, achieving an objective clinical response in 50% of patients, even in elderly patients with severe comorbidities. Their outcome was comparable to the results of prospective clinical trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

L.A. Devriese: Non-Financial Interests, Institutional, Advisory Role: BMS; Non-Financial Interests, Institutional, Advisory Role: Merck; Non-Financial Interests, Institutional, Advisory Role: MSD. J.B.A.G. Haanen: Non-Financial Interests, Institutional, Advisory Role: Achilles Therapeutics; Non-Financial Interests, Institutional, Advisory Role: Aimm; Non-Financial Interests, Institutional, Advisory Role: BioNTech; Non-Financial Interests, Institutional, Advisory Role: BMS; Non-Financial Interests, Institutional, Advisory Role: Gadeta; Non-Financial Interests, Institutional, Advisory Role: Immunocore; Non-Financial Interests, Institutional, Advisory Role: Ipsen; Non-Financial Interests, Institutional, Advisory Role: MSD; Non-Financial Interests, Institutional, Advisory Role: Merck Serono; Non-Financial Interests, Institutional, Advisory Role: Molecular Partners; Non-Financial Interests, Institutional, Advisory Role: Neogene Therapeutics; Non-Financial Interests, Institutional, Advisory Role: Novartis; Non-Financial Interests, Institutional, Advisory Role: Pfizer; Non-Financial Interests, Institutional, Advisory Role: Roche/Genentech; Non-Financial Interests, Institutional, Advisory Role: Sanofi; Non-Financial Interests, Institutional, Advisory Role: Seattle Genetics; Non-Financial Interests, Institutional, Advisory Role: Third Rock Ventures; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: BioNTech; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.